Print this page    •   Back to Web version of article

Focus on Hepatitis: HIV/HCV Coinfection Exacerbates ESLD Risk

By Liz Highleyman

September 2006

Patients coinfected with HIV and hepatitis C virus (HCV) are more likely to develop end-stage liver disease (ESLD) compared to patients who are HCV-monoinfected, according to a study presented by French researchers at the XVI International AIDS Conference held August 13-18, 2006, in Toronto. However, the researchers found that HIV/HCV-coinfected patients who achieved a sustained virological response to hepatitis C therapy were no more likely to progress to ESLD than their HCV-monoinfected peers.

Most studies show that coinfected patients experience more rapid liver fibrosis progression than those who are HCV-monoinfected, although this may be less likely if HIV is well-controlled. Coinfected patients are also less likely to respond to interferon (IFN)-based therapy.

Firouzé Bani-Sadr (INSERM, Paris) presented data from a study of liver disease progression among HIV/HCV-coinfected patients in France. The researchers prospectively followed 248 HIV/HCV-coinfected patients who received pegylated interferon (PEG-IFN) or conventional IFN, both with ribavirin (RBV), for 48 weeks in the RIBAVIC trial. Overall, 29% achieved sustained virological response, or continued undetectable hepatitis C viral load, 24 weeks after the completion of therapy.

The average age of the patients was 42 years, 75% were men, and 59% had hard-to-treat hepatitis C genotypes 1 or 4. Most (81%) were taking antiretroviral therapy for HIV, about half had HIV viral loads below 200 copies/mL, and the average CD4 count was 567 cells/mm3. At the start of the study, 35% already had severe liver fibrosis or cirrhosis.

After an average follow-up period of 33 months, 17 events indicative of ESLD occurred in nine patients (4%). These events included liver decompensation (with symptoms such as severely elevated bilirubin, ascites, hepatic encephalopathy, or bleeding esophageal varices), hepatocellular carcinoma, need for liver transplant, and liver-related death. Six patients died of liver-related causes and two of other causes.

All cases of ESLD occurred in patients who did not achieve sustained virological response to anti-hepatitis C therapy, and all but one occurred in patients who had advanced fibrosis at the start of the study. End-stage liver disease did not occur in patients with severe fibrosis who permanently cleared HCV with treatment. Among non-responders, ESLD was more common among patients with advanced fibrosis who also had lower CD4 counts.

In a stratified analysis, the only independent risk factors for ESLD were cirrhosis or severe fibrosis at the start of the study (P3 (P=0.022), and lack of sustained virological response to antihepatitis C therapy (P=0.068).

In conclusion, the researchers stated, "Our study confirms that the rate of spontaneous hepatic decompensation in coinfected patients with asymptomatic cirrhosis is higher (7.4% per year) than in [HCV]-monoinfected patients (3% to 4% per year)." The researchers further recommended that "clinicians should consider the evidence that sustained virological response seems associated with a reduction in long-term morbidity and mortality related to hepatitis C" when discussing treatment options with patients.

Editor's Note: Reprinted with permission from www.aidsmap.com (first e-published August 22, 2006).

Reference

  1. Carrat F, Cacoub P, Pol S, et al. Three years assessment of the risk of endstage liver disease in HIV/HCV-coinfected patients treated for a chronic HCV infection. XVI International AIDS Conference. August 13-18, 2006. Toronto [Abstract TUAB0301].




This article was provided by International Association of Physicians in AIDS Care. It is a part of the publication IAPAC Monthly. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art39510.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.